

# PRESS RELEASE



October 13 2016, Lund, Sweden

## **Immunovia chosen as one of the three most innovative small to mid-companies in Europe 2016**

### ***Stars of Innovation nomination recognizes stellar performance since IPO***

(LUND, Sweden) — Leading Swedish diagnostics company Immunovia today announced that it has been shortlisted for the Stars of Innovation category in the European Small- and Mid-Cap Awards 2016. The nomination is recognition of the company's stellar performance since listing in Stockholm in December last year. From an initial 2 EUR, the share price has risen to 9.24 EUR, an increase of 386%, giving the company a valuation of 154 MEUR. During this period, Immunovia has made major progress in developing the first applications for its IMMray™ blood-based diagnostics platform. Multi-national trials have been initiated in leading clinical centers deploying IMMray™ PanCan-d for the early detection of pancreatic cancer and commercialization plans accelerated.

The European Small and Mid-Cap Awards aim to promote best practices and encourage more small and medium-sized enterprises (SMEs) to access capital markets via IPOs. This is a joint initiative of the European Commission, leading European securities exchanges and European Issuers. SMEs created the foundation for the European economy today and in the future. More than 98% of EU firms are SMEs, and they account for two thirds of all employment as well as nearly 60% of gross value added in the EU economy.

“We are delighted to have been nominated and chosen as one of the three most innovative small to mid-companies in Europe”, says Immunovia CEO Mats Grahn. “We are now building on the financial platform provided by the IPO to bring IMMray™ PanCan-d, the test for early detection to market and to achieve reimbursement firstly in the US and priority markets in the EU. We will then expand wider in EU and to selected Asian markets. In parallel we are looking at the autoimmune disease area, with our most advanced studies in SLE or Lupus, as well as in other cancer areas such as prostate cancer.”

### **Link to European small and mid cap Awards 2016**

#### **For further information, contact:**

Mats Grahn, CEO Immunovia AB

Phone: +46 (0)70-532 02 30

E-mail: mats.grahn@immunovia.com

#### **About Immunovia**

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and

therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: [www.immunovia.com](http://www.immunovia.com))

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company's Certified Adviser. For more information, please visit [www.immunovia.com](http://www.immunovia.com).

###